[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100432662":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":25,"responsibleParty":113,"collaborators":115,"id":122,"slug":7,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":7,"eligibilityCriteria":127,"healthyVolunteers":123,"sex":128,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":7,"studyType":134,"phases":7,"briefSummary":135,"conditions":136,"keywords":7,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Haukeland University Hospital","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Biomarker analysis","Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months",[13],{"name":14,"affiliation":5,"role":15},"Mette Pernille Myklebust, PhD","PRINCIPAL_INVESTIGATOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","+47 41684492","mette.pernille.myklebust@helse-bergen.no",{"name":22,"role":18,"phone":23,"phoneExt":7,"email":24},"Olav Dahl, PhD","+47 55972081","olav.dahl@helse-bergen.no",[26,39,53,68,82,97],{"facility":5,"status":27,"city":28,"state":7,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Bergen","5021","Norway",{"type":32,"coordinates":33},"Point",[34,35],5.32415,60.39299,{"lat":35,"lon":34},[38],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":20},{"facility":40,"status":27,"city":41,"state":7,"zip":42,"country":30,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"Haugesund Hospital","Haugesund","5528",{"type":32,"coordinates":44},[45,46],5.268,59.41378,{"lat":46,"lon":45},[49],{"name":50,"role":18,"phone":51,"phoneExt":7,"email":52},"Bogdan Stefan Bercea, MD","+47 52 73 20 00","bogdan.stefan.bercea@helse-fonna.no",{"facility":54,"status":55,"city":56,"state":7,"zip":57,"country":30,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Oslo University Hospital","NOT_YET_RECRUITING","Oslo","0379",{"type":32,"coordinates":59},[60,61],10.74609,59.91273,{"lat":61,"lon":60},[64],{"name":65,"role":18,"phone":66,"phoneExt":7,"email":67},"Helene Negaard, MD, PhD","+47 22 93 40 00","UXHEGA@ous-hf.no",{"facility":69,"status":27,"city":70,"state":7,"zip":71,"country":30,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"University Hospital of North Norway","Tromsø","9038",{"type":32,"coordinates":73},[74,75],18.95508,69.6489,{"lat":75,"lon":74},[78],{"name":79,"role":18,"phone":80,"phoneExt":7,"email":81},"Hege S. Haugnes, MD, PhD","+47 77 75 43 42","hege.sagstuen.haugnes@unn.no",{"facility":83,"status":55,"city":84,"state":7,"zip":85,"country":86,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Sahlgrenska University Hospital","Gothenburg","41345","Sweden",{"type":32,"coordinates":88},[89,90],11.96679,57.70716,{"lat":90,"lon":89},[93],{"name":94,"role":18,"phone":95,"phoneExt":7,"email":96},"Anna G. Bergdahl, MD, PhD","+46 31 342 90 26","anna.grenabo@vg.region.se",{"facility":98,"status":27,"city":99,"state":7,"zip":7,"country":86,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Karolinska University Hospital","Stockholm",{"type":32,"coordinates":101},[102,103],18.06871,59.32938,{"lat":103,"lon":102},[106,109],{"name":107,"role":18,"phone":7,"phoneExt":7,"email":108},"Anna Thor, MD","anna.thor@ki.se",{"name":110,"role":18,"phone":111,"phoneExt":7,"email":112},"Anders Kjellman, MD, PhD","+46 073 699 52 58","anders.kjellman@sll.se",{"type":114,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[116,117,118,120,121],{"name":98,"class":6},{"name":83,"class":6},{"name":119,"class":6},"Helse Fonna",{"name":69,"class":6},{"name":54,"class":6},"100432662",false,"NCT04914026","MicroRNA as Markers in Testicular Cancer","MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours","Inclusion Criteria:\n\n* Patients with suspected testicular cancer, referred to orchiectomy.\n* Patients diagnosed with testicular germ cell cancer.\n* Age 18-70 years of age.\n* Must be able receive information and to consent.\n\nExclusion Criteria:\n\n* Other prior or concomitant malignancy (other than testicular cancer).\n* Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.","MALE","18 Years","70 Years",{"count":132,"type":133},350,"ESTIMATED","OBSERVATIONAL","The main objective of this study is establish the performance of miR371 in management of testicular cancer",[137,138,139,140,141,142,143,144],"Testicular Germ Cell Cancer","Seminoma","Non-Seminoma Testicular Cancer","Stage I Testicular Cancer","Stage II Testicular Cancer","Stage III Testicular Cancer","Stage IV Testicular Cancer","Relapse Testicular Cancer","2022-08-05",{"date":147,"type":148},"2022-08-08","ACTUAL",{"date":150,"type":148},"2016-12-31",{"date":152,"type":133},"2026-12-31",{"name":5,"class":6},6]